Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nifedipine
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Topical, Sublingual
01
Overview
Nifedipine is a small molecule drug in the dihydropyridine subclass of calcium channel blockers. It is primarily used to treat hypertension (high blood pressure) and angina pectoris (chest pain), including both chronic stable angina and vasospastic angina. Nifedipine works by inhibiting L-type voltage-gated calcium channels in vascular smooth muscle and myocardial cells. This action reduces peripheral arterial resistance and dilates coronary arteries by preventing the influx of calcium ions during depolarization. The result is relaxation of blood vessels (vasodilation), decreased cardiac workload, increased oxygen supply to the heart muscle, and reduced blood pressure[1][2][4][5]. Nifedipine may also be used off-label for conditions such as Raynaud's phenomenon and anal fissures[7]. It is available as immediate-release capsules or extended-release tablets taken orally.
- Brand names
- Adalat CCAfeditab CRNifediac CCNifedical XLProcardiaProcardia XLAdalatTensipineValni
- Other names
- nifedipine extended-releasenifedipine GITSnifedipine CR
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNB2 (Voltage-gated calcium channel β2 subunit)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)
Beyond the preview
Go deeper on nifedipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nifedipine.